anhydroicaritin

Anhydroicaritin is a naturally occurring **flavonoid compound** derived from the roots of *Epimedium brevicornu Maxim* and also found in *Boswellia carterii*.[1][2] It exhibits significant **immunosuppressive, antioxidant, antiosteoporosis, estrogen-regulating, and antitumor properties**.[1][2] Anhydroicaritin has demonstrated the ability to stimulate bone mineralization, improve obesity and hyperlipidemia, ameliorate insulin resistance, and exert protective effects in inflammatory models such as peritonitis in mice.[1] Mechanistically, it modulates several targets including AMPK, mTOR, GPX1, NO, interleukin receptors, TNF-α, NOS, and calcium channels, and is associated with suppression of SREBP activation and regulation of epithelial–mesenchymal transition (EMT) in various disease models, notably breast cancer and hepatocellular carcinoma.[1][4][7] In preclinical models, it demonstrated anti-metastatic and anti-proliferative effects, notably via upregulation of glutathione peroxidase 1 (GPX1), influencing prognostic markers and signaling pathways such as PI3K/AKT.[4][7] No approved pharmaceutical use or marketed brand is identified; it is studied experimentally as a research chemical.[2][4]

Other names

β-anhydroicaritinAHI